Agnete Kirkeby is an Associate Professor and group leader at the Novo Nordisk Foundation for Stem Cell Medicine (reNEW) at University of Copenhagen (Denmark) and at the Wallenberg Center for Molecular Medicine at Lund University (Sweden). The Kirkeby group has unique expertise in xenotransplantation and in using human pluripotent stem cells for production of subtype-specific human neurons, including also high-purity cultures of ventral midbrain dopamine neurons. This work has led to a European-based development of a stem cell treatment for Parkinson’s Disease (STEM-PD), which entered clinical trial in 2022 in Sweden (https://clinicaltrials.gov/ct2/show/NCT05635409). The group further produces various other different types of neurons and glial cells for use in regenerative therapy and disease modelling, and also studies early brain development using human stem cell and advanced microfluidic culturing techniques to model the developing human fetal neural tube.
Co-PI (Core Leadership)
Agnete Kirkeby, PhD
University of Copenhagen
Agnete Kirkeby is an Associate Professor and group leader at the Novo Nordisk Foundation for Stem Cell Medicine (reNEW) at University of Copenhagen (Denmark) and at the Wallenberg Center for Molecular Medicine at Lund University (Sweden). The Kirkeby group has unique expertise in xenotransplantation and in using human pluripotent stem cells for production of subtype-specific human neurons, including also high-purity cultures of ventral midbrain dopamine neurons. This work has led to a European-based development of a stem cell treatment for Parkinson’s Disease (STEM-PD), which entered clinical trial in 2022 in Sweden (https://clinicaltrials.gov/ct2/show/NCT05635409). The group further produces various other different types of neurons and glial cells for use in regenerative therapy and disease modelling, and also studies early brain development using human stem cell and advanced microfluidic culturing techniques to model the developing human fetal neural tube.
